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Summary 
Objective 
Hypoglycaemia may be a frequent occurrence in young GH deficient patients and so 
we studied the response to fasting in children and adolescents with GH and/or cortisol 
deficiency.  
 
Methods 
20 patients (2-18y) fasted for 14h (2200-1200h) on 2 occasions as part of a 
randomised cross-over study. 14 had pituitary hormone deficiency (PHD) including 
GH deficiency (GHD). 7 of the 14 were ACTH sufficient (PHDC+) and 7 ACTH 
deficient (PHDC-). 6 had primary adrenal failure (PAF). Subjects administered or 
omitted their normal dose of evening GH and/or morning hydrocortisone. Glucose, 
insulin, GH, cortisol, ketones and catecholamines were measured at 04.00h and 
regularly from 0700h to 1200h. Insulin sensitivity was assessed by HOMA and 
hypoglycaemia defined as a blood glucose less than or equal to 3.3 mmol/l. 
 
Results 
BG was related to age and Body Mass Index on treatment but no subject became 
hypoglycaemic on or off therapy prior to 0700h. 5 children (aged 3,4,7,8 and 11y) 
were hypoglycaemic between 0700h and 1200h off treatment. There was a positive 
relationship between GH AUC and minimum BG in patients with PHD on treatment 
(r2=0.45, p=0.012) with increased insulin sensitivity off treatment. Increased cortisol 
levels were seen in PHDC+ patients off GH (p<0.001). A negative relationship was 
observed between minimum BG and adrenaline (r2=0.37, p=0.01), ketone bodies (r2= 
- 0.20, p=0.05) and NEFA (r2= - 0.35, p=0.02). Noradrenaline levels were reduced in 
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patients with PHDC-. Low BMI (on treatment) and young age (off treatment) were 
determinants of low blood glucose levels in a multiple regression model. 
 
Conclusions 
Unrecognised overnight hypoglycaemia in children and adolescents on pituitary 
hormone replacement is uncommon but BG levels quickly become abnormal when 
treatment and meals are omitted. The insulin antagonistic actions of GH are important 
in preventing hypoglycaemia. Patients with PHD have altered sympathetic nerve 
activity.  
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Introduction 
 It has been known for many years that children with growth hormone 
deficiency (GHD) and ACTH deficiency are susceptible to hypoglycaemia before 
they are treated.1, 2, 3 Young children are particularly vulnerable with reduced 
gluconeogenesis, increased glucose utilisation, reduced fat mobilisation and ketone 
body generation potentially contributing to susceptibility. The normal child can fast 
for approximately 12 hours without any change in blood glucose (BG) concentrations 
but a more prolonged fast of 30 hours results in values around 3mmol/l 4. Lower BG 
and insulin concentrations are seen in the very young.4, 5  
 A surprising vulnerability of children and adolescents with GHD to 
hypoglycaemia was  reported more recently by Houdjik and colleagues.6 In a study 
designed to determine the pharmocokinetics of GH administered using 2 different 
delivery devices, GH was omitted for 3 nights and then a single dose (2IU/m2) was 
given at 1800h. BG was measured at intervals overnight and all 16 subjects were 
found to have a BG <2.6mmol/l on at least one of the two study nights.  
 As many as 50% of children receiving GH treatment in the UK fail to comply 
fully with treatment.7 This can be improved with patients and family education8,9 but 
the fact remains that less than a quarter of adolescents with chronic disorders comply 
fully with treatment regimens.10  
 We felt that the possibility of unrecognised overnight hypoglycaemia in our 
patients with GH and or primary / secondary adrenal insufficiency was an important 
issue that warranted further study. The findings of Houdjik and colleagues6 were 
intriguing in light of the relative infrequency with which neonates with isolated GHD 
become hypoglycaemic11 and we were keen to establish how quickly poor compliance 
and missed meals might impact on glucose levels.  
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The primary aims of this study were, firstly, to establish whether overnight 
hypoglycaemia was a common occurrence in young people with GH and/or cortisol 
deficiency on their usual treatment regimen and, secondly, to examine the impact of 
missing one dose of GH and / or hydrocortisone on BG concentrations during an 
overnight and morning fast.  
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Subjects and Methods 
 
Patients 
 Local Ethical Committee approval was obtained for these studies. 
14 children with pituitary hormone deficiency (PHD) and 6 with primary adrenal 
failure were recruited from the paediatric and adolescent endocrinology clinics at the 
Royal Victoria Infirmary in Newcastle-upon-Tyne. This was an observational study 
and we hoped to recruit a similar number of patients to that studied by Houdjik and 
colleagues.6 In this study hypoglycaemia had been a striking feature in all 16 patients 
and we anticipated that we would be able to recruit a similar number from our service, 
recognising that only some families would agree to participate. Of the patients with 
PHD, 7 had GH deficiency but were ACTH sufficient (PHDC+) whilst 7 had GH and 
ACTH deficiency (PHDC-). Patients were aged 3-18 years (median age 11.6 yrs) and 
all had a body mass index standard deviation score (BMISDS) between 2.5 SD above 
and below the mean.12 Patient details are shown in Table 1.  
 The diagnosis of PHD was made on the basis of the history, clinical 
examination, biochemical testing and, in the case of 2 children presenting with a 
craniopharyngioma, the pre-and post operative biochemistry as well as the operation 
record. Both of these patients had post-operative cranial diabetes insipidus. When 
interpreting biochemical testing, GH deficiency was defined as a peak GH to insulin-
induced hypoglycaemia (ITT) or following glucagon stimulation that was less than 
5mcg/l (13mU/l). GH production represents a continuum and we were keen to ensure 
that children were at the more severe end of this spectrum.13 ACTH deficiency was 
defined as a peak cortisol response to ITT or glucagon stimulation testing of less than 
500nmol/l. All of the patients who had isolated GHD had undergone cranial magnetic 
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resonance imaging (MRI) and had characteristic features of PHD.14 The patients with 
primary adrenal failure had congenital adrenal hypoplasia due to a mutation in 
NROB-1 (n=2), antibody positive autoimmune Addison’s disease (n=2) and isolated 
glucocorticoid deficiency (n=2). Patients on GH received a dose (0.5 to 0.8 
mg/m2/day) that maintained an age appropriate growth rate. Patients on 
hydrocortisone replacement were treated with a dose (7.7 – 12.5mg m2/day) that kept 
them free of symptoms attributable to glucocorticoid deficiency. GH was given by a 
single nightly subcutaneous injection and glucocorticoid replaced using a bd or tds 
hydrocortisone regimen.  
  
Study Protocol 
Each subject was admitted to hospital on 2 occasions as part of a randomised 
cross-over study involving a 14h overnight and morning fast. On one occasion 
subjects took their normal dose of GH and / or hydrocortisone and on the other 
occasion, 1 evening dose of GH was omitted and / or a single dose of hydrocortisone 
omitted on the morning of the study. We were therefore able to examine the impact of 
cortisol deficiency, GH deficiency and the combination of GH and cortisol deficiency 
on blood glucose levels. The two studies were conducted between 2 and 12 weeks 
apart and all studies were performed over a period of 11 months. 
 Patients were admitted in the afternoon and an intravenous cannula inserted 
for blood sampling. Height, weight, and pubertal status were recorded. Children were 
encouraged to undertake their normal physical activities and to take their medication 
consistently prior to each study with a similar diet on the evening of the two studies. 
The patients fasted from 2200h until 1200h the following day. Blood was taken at 
0400h for the measurement of BG and then at intervals from 0700h until 1200h. BG, 
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GH and cortisol were measured at 20 minute intervals, insulin, adrenaline and 
noradrenaline at hourly intervals and intermediary metabolites (non-esterified free 
fatty acids or NEFA’s, alanine, aceto-acetate and beta-hydroxybutyrate) at 0700h and 
again at 1200h. Blood samples were spun and separated immediately after sampling 
with biochemical assays conducted the same day (glucose, GH, cortisol) or the 
samples frozen at -80oC for assays conducted at a later date.  
Insulin sensitivity (IS) was calculated hourly using the computerised HOMA model.15  
 
Hypoglycaemia 
 Blood glucose concentrations are a continuous variable but for the purpose of 
this study hypoglycaemia was defined as a blood glucose concentration less than or 
equal to 3.3mmol/l.  
 
Laboratory methods 
 Glucose was measured using the hexokinase method (Olympus system – intra-
assay CV 1.1%, inter-assay CV of 2.7% at 3.5mmol/l). GH was measured by two site 
chemiluminescence (Nichols Advantage HGH assay – intra-assay CV of 3%, inter-
assay of 7%). Cortisol was measured using a competitive immunoassay and direct 
chemiluminescence (ADVIA Centaur assay - intra-assay CV of 3%, inter-assay CV 
12%). Insulin was measured using an enzyme linked immunosorbent assay (DAKO – 
intra-assay CV of 5%, inter-assay CV 4.5 – 5.3%). Catecholamines were measured 
using in-house HPLC (inter-assay CV 10% at 0.48 nmol/l and 6.6% at 7.08 nmol/l). 
Intermediary metabolites were measured using a Cobas Centrifugal Fast Analyser 
(alanine intra-assay CV 2.3 % at 0.21 mmol/l and inter-assay CV 7.0% at 0.19 
mmol/l; acetoacetate intra-assay CV 5.0 % at 0.26 mmol/l and inter-assay CV 6.0% at 
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0.30 mmol/l; betahydroxybutyrate intra-assay CV 2.0 % at 1.61 mmol/l and inter-
assay CV 6.8% at 1.37 mmol/l) and NEFAs were measured enzymatically using a 
WAKO NEFA C Test kit (intra-assay CV 3.1% at 0.1mmol/l and 2.1 at 1.0 
mmol/l and inter-assay CV 12% at 0.1mmol/l and 3.8% at 1.0mmol/l). 
. 
Statistics  
 Demographic data is expressed as mean +/- 1 standard deviation (SD) or 
median and range depending on whether it was normally distributed or not. Paired 
data for each subject were analysed using paired t-tests and area under the curve was 
used as a summary measure. Between group differences were analysed using 
ANOVA and Fisher’s pairwise comparisons. Spearman correlation co-efficients were 
calculated for linear relationships and multiple regression analysis was performed 
using a forward selection method with variables that could potentially affect blood 
glucose concentrations. Cortisol, GH and adrenaline production were calculated using 
the trapezoid rule for area under the curve (AUC). A summary of IS over the morning 
was also calculated in this way. IS, ketone body and NEFA concentrations were all 
normalised by log transformation prior to statistical analysis. 
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Results  
Patient characteristics 
There were no significant differences between the groups in terms of age or BMI.  
 
Overnight BG concentrations  
 No child with PHD was found to be hypoglycaemic at 0400h on or off  
therapy and there was no difference between study nights (BG=5.4+1.0 mmol/l on 
treatment v 4.8+0.4 mmol/l off treatment; NS). None of the children with adrenal 
failure become hypoglycaemic overnight (BG=5.3+0.5 mmol/l). When treatment was 
omitted, children with PHDC- had lower BG concentrations at 0400h than those with 
PAF (4.7+0.4mmol/l v 5.4+0.5mmol/l; p=0.03).  
 
Minimum BG concentrations between 0700h and 1200h  
 No child with PAF or PHD became hypoglycaemic on treatment. When 
treatment was omitted, 5 children had BG concentrations <3.3mmol/l. 4 of the 
children had PHD (3 PHDC- and 1 PHDC+) and one child had PAF. Children with 
PHD had significantly lower BG concentrations on the morning when treatment had 
been omitted when assessed by either BG AUC (p=0.006) or by minimum BG 
between 0700h and 1200h (4.4 +0.5 mmol/l v 3.9 +0.5 mmol/l, p=0.008).  
The difference in blood glucose concentrations between the 2 study nights in the 3 
groups of patients is shown in figure 1.  
 
Relationship between BG concentrations, age and BMISDS 
 There was a positive relationship between BG concentrations at 0400h and age 
off therapy (r2=0.22; NS on treatment and r2=0.38; p=0.012 off treatment). There was 
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also a relationship between minimum BG throughout the study and age on and off 
treatment (r2=0.20; p=0.05 on treatment; r2=0.46; p=0.001 off treatment) and glucose 
AUC and age (r2=0.57; p<0.001 on treatment; r2=0.20; p=0.05 off treatment). The 
minimum BG concentration between 0700h and 1200h was related to age in those 
with PHD both on and off treatment (r2=0.49, p=0.008 and r2=0.38, p=0.018) but not 
in those with PAF (r2=0.60, NS). BG values at 0400h and at 0700h were positively 
related to BMISDS in all patients on treatment (r2=0.44, p=0.004 and r2=0.46, 
p=0.001) but not off treatment (r2=0.01, NS and r2=0.00, NS). BMISDS was related to 
BG in patients with PHD (C+ and C- ) at 0400h, 0700h (r2=0.69, p=0.001), 1200h 
(r2=0.65, p=0.001) and also to minimum BG concentrations (r2=0.61, p=0.002) on 
replacement. There was no relationship between these variables when treatment was 
omitted.  
 
GH levels and GH counter-regulation 
a) GH  
 There was a positive relationship between the GH AUC and minimum BG in 
patients with PHD on treatment (r2=0.45, p=0.012). There was no relationship 
between minimum glucose concentration and GH AUC in patients with PAF off 
treatment (r2=0.59, NS).  
b) Cortisol  
 When patients with PHDC+ omitted their evening GH, the cortisol AUC was 
higher than when treatment had been given (2991 + 1073 nmol/l versus 2374 + 
756nmol/l; p= 0.01). There was no relationship between cortisol AUC and glucose 
concentrations, either on or off treatment. 
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c) Adrenaline  
 There was no difference in the adrenaline concentrations between the two 
study nights and no difference in the adrenaline concentrations as assessed by AUC 
between those with PHD and those with PAF (Table 2). When treatment was omitted 
there was a negative relationship between minimum BG and adrenaline 
concentrations in the group as a whole (r2=0.37, p=0.01).  
d) Noradrenaline 
 There was no difference in the noradrenaline concentrations as assessed by 
AUC between those with PHD and adrenal failure. However when the groups were 
analysed by ANOVA patients with PHDC- had significantly lower noradrenaline 
concentrations than those with PHDC+ on and off treatment (p< 0.05, Table 2).  
e) Insulin sensitivity  
 Children with PHD (both PHDC+ and PHDC-) were more insulin sensitive on 
the morning on which medication had been omitted (p=0.05 and p=0.01) respectively 
(Figure 2). There was a negative relationship between IS and age in the group as a 
whole (on treatment r2=0.16, NS, off treatment r2=0.24, p=0.03). There was a negative 
relationship between IS and BMI SDS when treatment was given (r2=0.42, p=0.003) 
but not when treatment was omitted (r2=0.08, NS). 
 
Intermediary metabolites 
a) Alanine  
 On treatment, children with PHDC- had  higher concentrations of alanine than 
those in the other 2 groups at 0700h  (ANOVA p=0.03) There was no relationship 
between alanine concentrations at the end of the fast and age when treatment was 
given but when treatment was omitted, the younger children had lower alanine 
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concentrations (r2=0.79, p=0.011). There was no relationship between alanine 
concentrations and minimum BG concentrations when treatment had been given in 
either those with PHD or PAF, but when treatment was omitted, there was a positive 
relationship between alanine and minimum BG in those with PHD (r2=0.56, p=0.002). 
b) NEFAs and ketones 
 There was no difference in the NEFA or total ketone bodies (TKB; 
acetoacetate + β-hydroxybutyrate) between the 3 groups on and off treatment, at the 
end of the fast. There was no relationship between age and TKB or NEFA 
concentrations either on or off treatment in the group as a whole (data not shown). On 
treatment TKB and NEFA concentrations were not related to minimum BG, but when 
treatment was omitted, there was a negative relationship (TKB r2= - 0.20, p=0.05; 
NEFA r2= - 0.35, p=0.02). 
  
Multiple regression analysis 
A forward selection multiple regression model was performed using the variables age, 
BMI SDS, GH AUC, cortisol AUC, adrenaline AUC, NEFA and TKBs, to establish 
which were significant determinants of minimum blood glucose concentrations. On 
treatment the only significant variable was BMISDS, p=0.005, accounting for 35% of 
the variability. Off treatment the significant determinants were age (positive 
relationship) and NEFA (negative relationship), p<0.001, accounting for 55% of the 
variability.  
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Discussion 
We defined hypoglycaemia as a BG less than or equal to 3.3 mmol/l. This 
level was chosen for 3 reasons. Firstly, cognitive function becomes impaired at this 
blood glucose concentration.16,17,18 Secondly, neurophysiological changes can be 
observed in children when blood glucose concentrations are at this level19 and finally, 
a counter-regulatory hormone response was expected when BG concentrations fell to 
3.3mmol/l.17, 20  Jaquert and colleagues21 studied 10 children with either GH 
deficiency, GH and TSH deficiency or panhypopituitarism. The authors defined 
normal blood glucose values as being in the range 3.2 to 5.2 mmol/l but 
hypoglycaemia as a BG less than or equal to 2.6 mmol/l. 9 of the 10 patients became 
hypoglycaemic during a 24h fast (all patients if our definition of hypoglycaemia is 
used) but it is of note that these patients were generally younger than those studied by 
ourselves. They were also fasted for a longer and clinically less relevant period of 
time (24h).   
  In contrast to the work of Houdjik and colleagues6 we have not found any 
evidence of hypoglycaemia overnight in children or adolescents with GHD and / or 
cortisol deficiency on or off treatment. The patients in both studies received similar 
doses of GH at the same time in the evening but the fact that our patients were 
younger might have been expected to make them more susceptible to hypoglycaemia. 
Our definition of hypoglycaemia (less than or equal to 3.3 mmol/l) when compared to 
that of Houdjik and colleagues (less than 2.5mmol/l) serves to highlight the difference 
in behaviour of the two study groups. There are a number of possible explanations for 
the lower BG concentrations seen in Houdjik and colleague’s study. Firstly, the 
adolescents omitted three doses of GH in the nights prior to sampling in contrast to 
our study where children either took their GH as normal or were studied after the 
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omission of one dose. The cumulative effect of the three omitted doses may therefore 
have rendered patients more susceptible to low BG concentrations. Secondly, BG 
concentrations were measured more frequently in Houdjik and colleague’s study and 
we may have missed a short episode of overnight hypoglycaemia. However we 
believe this is unlikely since the 0400h sample was taken at the time at which the 
minimum BG concentrations had been observed. Finally, it is possible that the 
patients may have been quite different in terms of factors such as diet and preceding 
activity levels. However we are not aware of any selection criteria that are likely to 
lead to such profound differences in study findings. 
As the fast continued into the morning there was evidence of decompensation 
when medication was omitted. 25% of our patients with PHDC+, PHDC- and PAF 
became hypoglycaemic during the morning, with a BG concentration less than or 
equal to 3.3mmol/l. Children with both GH and ACTH deficiency were, as expected, 
more susceptible with 3 from 7 becoming hypoglycaemic. Concentration is impaired 
in the well child if a breakfast containing complex carbohydrates is omitted.22 
Children with GH or cortisol deficiency who miss breakfast could exacerbate 
differences in neurological performance that have been described between them and 
their peers.23 BG concentrations were related to age, in contrast to an earlier study in 
fasting children with hypopituitarism,21 but it was not just the youngest children who 
became hypoglycaemic and therefore any advice regarding hypoglycaemia should be 
given to all patients with PHD. 
Studies with radioisotopes or with Magnetic Resonance Spectroscopy are the 
best way to assess the precise mechanisms that result in low blood glucose levels. 
However the positive relationship between GH AUC and minimum BG in patients 
with PHD underlines the pivotal role of GH in maintaining glucose concentrations in 
 16 
the fasting child. We did not find a difference between the GH AUC on and off 
treatment in those with PAF which may reflect the small numbers studied or the fact 
that GH secretion in response to spontaneous hypoglycaemia is not a good measure of 
GH reserve.24 However, overnight BG levels were lower in patients making neither 
GH or cortisol (PHDC-) versus children unable to make just cortisol (PAF).  
The patients with PHDC+ produced more cortisol when treatment was omitted, 
despite the fact that only 1 child in this group became hypoglycaemic. This suggests 
that cortisol production is affected by absolute glucose levels and not just a particular 
glycaemic threshold. 
When treatment was administered there was a negative relationship between 
IS and BMISDS, consistent with the findings of other authors who used the HOMA 
model.25 Multiple regression analysis identified a relationship between BMISDS and 
minimum BG and the fact that slim patients may be more susceptible to 
hypoglycaemia is a simple point that needs to be borne in mind by clinicians. The 
relationship between BMISDS and IS as well as minimum BG was lost when 
treatment was omitted which we suspect is in part a reflection of the impact of GH 
and cortisol on fuel mobilisation from fat. The fact that low BG was inversely related 
to NEFA levels in the multiple regression model may be linked to catecholamine 
production and associated fat mobilisation as part of the metabolic response to fasting 
and low BG levels.  
The development of the adrenal medulla is dependent upon normal exposure 
to glucocorticoids antenatally.26 There is bi-directional signalling between the adrenal 
cortex and medulla and glucocorticoids regulate the expression of enzymes involved 
in catecholamine synthesis (tyrosine hydroxylase,27, 28 dopamine-β-hydroxylase29 and 
phenylethanolamine-N-methyltransferase30) and catecholamines enhance 
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adrenocortical steroidogenesis by stimulation of cytochrome P450 enzymes.31 
Children with CAH have been observed to have lower morning adrenaline 
concentrations and lower adrenaline concentrations after exercise than normal 
children.32 The interpretation of circulating noradrenaline concentrations is more 
difficult because it is a neurotransmitter that is produced both from the adrenal glands 
and from the sympathetic chain. In terms of cortisol production these groups may be 
relatively heterogeneous since the ACTH deficiency in PHD may evolve over time33 
and 3 of the patients had acquired PHD as a result of craniopharyngiomas and trauma. 
The patients with PAF also presented at different stages of childhood.  
When treatment was omitted, those with PHDC- had lower noradrenaline 
concentrations. Voorhess et al.34 found that children with GHD but ACTH sufficient 
had no increase in noradrenaline in response to insulin induced hypoglycaemia 
whereas short normal children had a two fold increase, although others have observed 
a normal response to hypoglycaemia in those with GHD.35 These observations may 
reflect a developmental defect of the sympathetic chain as well as the hypothalamo-
pituitary axis in some of these patients.  
 We conclude that children and adolescents with GH and ACTH/cortisol 
deficiency are susceptible to hypoglycaemia when a single dose of medication is 
omitted. The susceptibility is greatest in, but not confined to, the younger children 
who are both GH and ACTH deficient and in whom noradrenaline production is also 
compromised. We have demonstrated evidence of counterregulation with increased 
cortisol concentrations in those with PHD who were ACTH sufficient. We have also 
demonstrated failure to mobilise alternative fuels as a likely mechanism behind the 
low blood glucose concentrations that we observed. The importance of regular meals 
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and compliance with medication should be emphasised to this group of patients and 
their parents, particularly in those who are young and slim. 
. 
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Table 1 Patient Characteristics 
 
Patient 
No.  
Age Sex Diagnosis BMI 
(SDS) 
GH 
(mg/m2/d) 
H/C 
(mg/m2/d) 
Other hormone 
replacement 
1 13.6 M PAF 21.4 
(1.2) 
* 11.67 Fludrocortisone 
2 3.7 M PAF 15.0 
(-0.7) 
* 11.67  
3 16.4 M PAF 25.4 
(1.7) 
* 9.09 Testosterone 
4 18.7 M PAF 21.0 
(-0.1) 
* 12.12 Testosterone 
5 14.9 F PAF 17.2 
(-1.2) 
* 10.94 Fludrocortisone 
6 7.6 M PAF 15.0 
(-0.5) 
* 12.50  
7 16.6 M PHDC+ 18.5 
(-0.8) 
0.59 * Testosterone 
8 4.8 M PHDC+ 15.0 
(-1.5) 
0.50 *  
9 11.7 F PHDC+ 17.4 
(-0.2) 
0.55 * Thyroxine 
10 6.4 F PHDC+ 16.6 
(0.7) 
0.56 * Thyroxine 
11 15.1 M PHDC+ 17.9 
(-0.7) 
0.71 * Thyroxine 
12 8.3 M PHDC+ 17.9 
(1.1) 
0.76 *  
13 17.0 M PHDC+ 28.4 
(2.2) 
0.77 *  
14 12.5 M PHDC- 25.4 
(2.3) 
0.65 8.67 Thyroxine  
Testosterone 
15 4.2 M PHDC- 16.9 
(0.9) 
0.51 7.69 Thyroxine 
16 11.5 F PHDC- 24.8 
(2.2) 
0.60 8.89 Thyroxine 
17 15.3 F PHDC- 26.8 
(1.9) 
0.75 8.33 Thyroxine 
Oestrogen 
18 6.7 M PHDC- 16.2 
(0.5) 
0.51 9.87 Thyroxine 
DDAVP 
19 7.8 M PHDC- 15.5 
(-0.1) 
0.64 8.15 Thyroxine  
DDAVP 
20 8.9 M PHDC- 14.6 
(-0.9) 
0.80 10.00 Thyroxine 
 
PAF – Primary adrenal failure; PHDC+ - Pituitary Hormone Defiiency, cortisol 
sufficient; PHDC- - Pituitary Hormone Deficiency, cortisol insufficient 
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Table 2.  
Adrenaline and Noradrenaline concentrations (area under the curve – AUC) during 
the morning fast. 
 
 
Adrenaline 
AUC 
0700h - 1200h 
Mean On 
treatment 
(nmol/l/300mins) 
SD Mean Off 
treatment 
(nmol/l/300mins) 
SD ‘p’ 
value 
PAF 1.7 0.6 1.8 0.8 NS 
PHDC+ 2.0 0.5 2.2 0.7 NS 
PHDC- 1.9 0.7 2.2 1.0 NS 
Between 
groups 
   NS    NS   
 
Noradrenaline 
AUC 
0700h - 1200h 
            
(nmol/l/300mins) 
         
(nmol/l/300mins) 
  
PAF 15.3 4.7 12.2 4.3 NS 
PHDC+ 15.0 4.0 15.8 3.1 NS 
PHDC- 10.1 0.8 9.8 2.6 NS 
Between 
groups 
p=0.03  p=0.04   
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Figure 1 
Difference in blood glucose concentrations (+ or – 1 SEM) between the 2 study nights 
(on and off treatment) in the 3 patient groups (O = PAF; ∇ = PHDC+;  ∆ = PHDC-). 
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Figure 2 
Difference in insulin sensitivity (with 1 SEM) between the study nights ‘on’ and ‘off’ 
treatment. 
 
 
